Beijing Tri-Prime Gene Pharmaceutical Co, Ltd. (Abbr.: Tri-Prime Gene, stock code: 837344) with a registered capital of RMB 121.81 million, specializes in R&D, production, and commercialization of modern biopharmaceuticals, establishing itself as a leader in both fundamental research and clinical application of gene engineering drugs in China.
Learn Moreeffective invention patents
1992~2025
Through optimization of vectors for the recombinant protein expression sγδTem in Escherichia coli, optimization of fermentation processes, and purification process improvements, we have taken the lead in China to innova... ...
By establishing a high-stability water solution technology platform for recombinant proteins, we have successfully developed water injections, nebulizers, drops, pre-filled syringes, and various dosage forms of interferon... ...
Currently, the long-acting technology of protein drugs mainly relies on polyethylene glycol (PEG) modification and albumin fusion expression, with industrial applications already realized for imported long-acting antagoni... ...
Tri-Prime Gene will design and establish a cellular therapy engineering center integrated into the company's new factory area for intelligent production and R&D base project construction. This platform possesses natural γ... ...